CELG News and Press, Celgene Corporation From 07/23/19

Jounce Therapeutics (NASDAQ: JNCE ) is up  41%  after hours in reaction to its updated partnership with Celgene (NASDAQ: CELG ) under which the latter has in-licensed global rights to JTX-8064, an LILRB2 receptor-targeting monoclonal antibody. More news on: Jounce Therapeutics,...

- Celgene licenses JTX-8064, resulting in $50.0 million upfront payment to Jounce - - Jounce retains full worldwide rights to vopratelimab, JTX‑4014 and all discovery programs - - Company to host conference call and webcast today at 5:00 p.m. ET - CAMBRIDGE, Mass., July ...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (y...

Read more ...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , iTunes...

OTEZLA reduced the number and pain of oral ulcers in the 12-week placebo-controlled Phase 3 RELIEF™ study With this third indication in the U.S., OTEZLA is the first and only treatment approved for oral ulcers associated with Behçet’s Disease Celgene Corporation...

BMY: Investment Thesis As of market close on Tuesday, July 16, 2019, Bristol-Meyers Squibb ( BMY ) share price was $44.45, and Celgene ( CELG ) share price was $91.53, a difference of $47.08. Under the takeover terms, Celgene shareholders receive one Bristol-Meyers Squibb ["BMS"] share, plus...

Gilead invests in Galapagos, confirms further consolidation in the Biotech/Pharma Space Look, I am no genius when it comes to biotech. The whole drug approval process requires an extra lifetime to get the hang of. That said, the economics of finding biotech drugs to fill a sales pipeline mak...

by Daniel Shvartsman The first half of 2019 saw a lot of green in the markets, as broader indices recovered from the brief bear market in the second half of 2018 and returned to new heights. Despite that, the wall of worry continued to grow, even if the specific concerns changed. Instead o...

My plan for my investment in NantKwest ( NK ) was to build a conservative position in anticipation that the market will start to identify the prospective upside in the stock. Indeed, NantKwest still has a couple of years from a potential product launch. Still, I expect CEO and founder Dr. Soon...